Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Clin Oncol. 2015 Feb;38(1):17-22. doi: 10.1097/COC.0b013e3182893f13.

Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.

Author information

1
The Hellenic Oncology Research Group (HORG), Athens, Greece.

Abstract

INTRODUCTION:

We conducted a feasibility study on docetaxel/capecitabine/cisplatin (DCX) with chemoradiotherapy as adjuvant treatment for gastric cancer patients.

METHODS:

Patients were scheduled to receive 2 cycles of DCX, followed by 50.4 Gy plus capecitabine as radiotherapy, followed by an additional 2-DCX cycles.

RESULTS:

From the 40 enrolled patients, 26 (65%) completed treatment as per protocol and 14 (35%) discontinued with the treatment (patients' refusal: n=6; adverse events: n=8). There were 2 toxic deaths. Grade >3 toxicity was 12.1% before and 13.3% after chemoradiotherapy. Disease progression was documented in 11 (27.5%) patients.

CONCLUSIONS:

No further development of this regimen is justified on the basis of poor tolerability in patients.

PMID:
23563209
DOI:
10.1097/COC.0b013e3182893f13
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center